Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15769MR)

This product GTTS-WQ15769MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15769MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15227MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ4256MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ7949MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ10441MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ9238MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ11454MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ14995MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ5271MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW